BG Medicine Q2 Revenues Spike; Company Withdraws FDA Submission for CardioScore Test
August 09, 2012
BG Medicine Q2 Revenues Spike; Company Withdraws FDA Submission for CardioScore Test
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- BG Medicine Posts 85 Percent Jump in Q1 Revenues, Appoints New CEO
May 10, 2013 / ProteoMonitor - BG Reports 257 Percent Jump in Q3 Revenues, May Offer CardioScore Through CLIA Lab as LDT
November 16, 2012 / ProteoMonitor - BG Medicine Fails to Meet Listing Requirement, Nasdaq Warns Firm
May 20, 2013 / GenomeWeb Daily News - With $10M in Funding and New Distribution Pact, Aviir Rolls out Protein Test for Cardiac Risk
March 1, 2013 / ProteoMonitor - Framingham Study Offers Mixed Message on Galectin-3 as Heart Failure Risk Marker
September 7, 2012 / ProteoMonitor